Heather Bresch, chief executive of the Mylan pharmaceutical company, has come under fire for her company’s handling of their EpiPen product. When Mylan acquired the EpiPen medication in 2007, Bresch referred to the project as, “her baby.” Bresch turned the $200 million project into a $1.1-billion-dollar business for Mylan, while she ascended to the highest position in Mylan.
The EpiPen is used to stop allergic reactions as soon as a victim is exposed. Something as minor as a bee sting can cause some people to have difficulty breathing, making the EpiPen an essential medical product for individuals with severe allergic reactions.
Mylan practically has a monopoly on the sale of EpiPens, owning 90% of the medical device’s market. Since their acquisition of EpiPen in 2007, the price for an EpiPen has increased by 400 percent! In 2007, the EpiPen cost users less than $100. Now the product is priced at over $600.
Coincidentally, CEO Heather Bresch’s salary has increased by 600% since 2007, reaching $18 million in 2015! Unfortunately, it appears Heather Bresch’s lavish salary has come at the expense of taxpayers and EpiPen users.
Despite repeated warnings from the Center for Medicaid Services, Mylan classified their EpiPen product as a generic drug, instead of a name-brand drug. This allowed Mylan to only pay 13% in rebate costs to state Medicaid programs, instead of the legally-required 23% rebate cost for name-brand products.
By classifying the EpiPen as a generic drug, Mylan allowed state Medicaid programs to cover the additional 10% rebate cost, placing an unnecessary burden on EpiPen users that need this medical device! While Mylan was cheating state Medicaid programs out of millions of dollars, their CEO was taking home an extravagant salary of $18 million!
Sign this petition to tell Senator Chuck Grassley, chairman of the Senate Judiciary Committee, to hold Mylan CEO Heather Bresch criminally accountable for her company’s actions!